london euretina
retina race

Comparison of 2 mineralocorticoid receptor antagonists in the treatment of central serous chorioretinopathy

Session Details

Session Title: New Drug Treatment and Technology I

Session Date/Time: Friday 18/09/2015 | 11:00-12:30

Paper Time: 11:08

Venue: Thalie.

First Author: : P.Carrai ITALY

Co Author(s): :    F. Pichi   F. Behar-Cohen   P. Nucci        

Abstract Details

PURPOSE:To compare spironolactone and eplerenone, mineralocorticoid receptor antagonists, as potential treatment for central serous chorioretinopathy

Setting:

This randomized, placebo-controlled, crossover clinical trial included 30 patients with central serous chorioretinopathy of at least 3-months duration, randomized 1:1:1 to 3 Groups.

Methods:

Group 1 patients were treated with 25 mg/day of oral spironolactone a week followed by 50 mg/day for 3 weeks, then switched to 50 mg/day oral eplerenone for 1 month; Group 2 patients were treated with 25 mg/day of oral eplerenone a week followed by 50 mg/day for 3 weeks, then switched to 50 mg/day oral spironolactone for 1 month; Group 3 patients were treated with 25 mg/day of oral placebo a week followed by 50 mg/day for 3 weeks, then switched to 50 mg/day oral spironolactone for 1 month. The primary outcome measure was the changes in central retinal thickness (CRT) recorded by optical coherence tomography, and the secondary outcomes included changes in best-corrected visual acuity (BCVA) and the percentage of eyes achieving complete resolution of subretinal fluid during the treatment period.

Results:

Central retinal thickness from baseline to crossover decreased significantly from 430.4 ± 163 µm to 340.8 ± 74 µm and from 399.25 ± 76 µm to 319.5 ± 91 µm, in Group 1 and 2 respectively. Two months CRT in Group 1 and 2 were 254.7 ± 96 µm and 287.7 ± 2 µm respectively. CRT of sham patients in Group 3 from 341.4 ± 83 µm at baseline to 331.7 ± 82 µm at crossover, then decreased to 237,6 ± 45 µm after crossing to spironolactone. In the crossover Group 1 and 2, mean initial BCVA was 44.7 ± 7 and 47.8 ± 4 ETDRS letters, improved by 6.2 and 5.8 letters at crossover, and remained stable at conclusion (P=0.91). BCVA of sham patients decreased during the first month, with an average loss of 3.5 letters, then increased or an average gain of 3.2 and 4.1 letters, respectively, 1 and 3 months after rollover.

Conclusions:

Both spironolactone and eplerenone are effective for the treatment of CSCR, even if spironolactone appears to have better anatomic outcomes and to achieve a faster resolution of subretinal fluid. Changing treatments from spironolactone to eplerenone did not result in further gains in visual acuity.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy